Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

IGMS
IGM Biosciences, Inc. Common Stock
stock NASDAQ

At Close
May 13, 2025 3:59:30 PM EDT
1.14USD-4.202%(-0.05)85,777
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 12, 2025 8:00:30 AM EDT
1.13USD-5.042%(-0.06)0
After-hours
May 13, 2025 4:27:30 PM EDT
1.11USD-2.632%(-0.03)13,274
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 5, 2022
07:00AM EST  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 10:30 a.m. EST.   GlobeNewswire Inc
Dec 16, 2021
07:34AM EST  10 Biggest Price Target Changes For Thursday   Benzinga
06:23AM EST  HC Wainwright & Co. Maintains Buy on IGM Biosciences, Lowers Price Target to $76   Benzinga
Dec 14, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2021   Benzinga
09:33AM EST  Morgan Stanley Downgrades IGM Biosciences to Equal-Weight, Lowers Price Target to $38   Benzinga
08:16AM EST  IGM Biosciences Says First Patient Dosed In MIV-818 Combination Study   Benzinga
Dec 13, 2021
02:36PM EST  Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; BELLUS Health Shares Spike Higher   Benzinga
01:08PM EST  Mid-Day Market Update: Nasdaq Drops Over 100 Points; Foghorn Therapeutics Shares Surge   Benzinga
10:48AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2021   Benzinga
10:03AM EST  Mid-Morning Market Update: Markets Open Lower; Pfizer To Acquire Arena Pharmaceuticals   Benzinga
09:53AM EST  Where IGM Biosciences Stands With Analysts   Benzinga
09:40AM EST  Stifel Maintains Buy on IGM Biosciences, Lowers Price Target to $65   Benzinga
09:31AM EST  Jefferies Maintains Buy on IGM Biosciences, Raises Price Target to $126   Benzinga
07:16AM EST  10 Biggest Price Target Changes For Monday   Benzinga
06:34AM EST  RBC Capital Downgrades IGM Biosciences to Sector Perform, Lowers Price Target to $51   Benzinga
Dec 11, 2021
01:32PM EST  - Data Presented Shows Novel Bispecific IgM Antibody is Active in Heavily Pre-treated Patients with Relapsed/Refractory NHL, including DLBCL and FL, and has a Favorable Safety Profile -   GlobeNewswire Inc
Dec 8, 2021
07:19AM EST  IGM Biosciences To Collaborate On The Study Of IgM And IgA Antibodies For The Prevention Of Malaria   Benzinga
07:00AM EST  Grant Agreement with the Bill & Melinda Gates Foundation Aims to Leverage IGMs Engineered IgM and IgA Antibodies to Address a Significant Driver of Morbidity and Mortality in Low- and Middle-Income Countries   GlobeNewswire Inc
Dec 6, 2021
04:05PM EST  IGM Biosciences to Host Conference Call and Webcast to Review   GlobeNewswire Inc
Nov 8, 2021
07:00AM EST  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 2:00 p.m. EST.   GlobeNewswire Inc
Nov 5, 2021
10:07AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021   Benzinga
09:44AM EDT  RBC Capital Maintains Outperform on IGM Biosciences, Lowers Price Target to $90   Benzinga
09:43AM EDT  Wedbush Upgrades IGM Biosciences to Outperform, Announces $82 Price Target   Benzinga
Nov 4, 2021
09:34AM EDT  IGM Biosciences Q3 EPS $(1.32) Down From $(0.66) YoY   Benzinga
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 11, 2021
04:07PM EDT  IGM Biosciences Reports Formation Of 2 Business Units: IGM Infectious Diseases, IGM Autoimmunity And Inflammation   Benzinga
04:05PM EDT  John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious Diseases   GlobeNewswire Inc
Sep 23, 2021
04:19PM EDT  IGM Biosciences To Present At Cantor's Global Healthcare Conference Sept. 29 At 3:20 p.m. EDT   Benzinga
04:05PM EDT  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will present at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021 at 3:20 p.m. EDT.   GlobeNewswire Inc
Sep 7, 2021
07:00AM EDT  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in three upcoming investor conferences:   GlobeNewswire Inc
Aug 26, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021   Benzinga
07:59AM EDT  Morgan Stanley Initiates Coverage On IGM Biosciences with Overweight Rating, Announces Price Target of $100   Benzinga
Aug 16, 2021
08:48AM EDT  Wedbush Maintains Neutral on IGM Biosciences, Raises Price Target to $82   Benzinga
Aug 9, 2021
05:00PM EDT  IGM Biosciences S-3 Shows Registration For 24.75M Share Common Stock Offering Via Selling Shareholders   Benzinga
04:44PM EDT  IGM Biosciences Q2 EPS $(1.16) Down From $(0.62) YoY   Benzinga
04:07PM EDT  IGM Biosciences Announces Second Quarter 2021 Financial Results   GlobeNewswire Inc
Jun 3, 2021
07:06AM EDT  IGM Biosciences Highlights Expansion Of IgM Platform Into Infectious Diseases; Co. Also Highlights Publication Of Preclinical Data In Nature   Benzinga
07:01AM EDT  IGM Biosciences Announces Expansion of IgM Platform into   GlobeNewswire Inc
May 26, 2021
07:00AM EDT  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021 at 1:00 p.m. EDT.   GlobeNewswire Inc
May 12, 2021
07:00AM EDT  IGM Biosciences to Present at the 2021 RBC Capital Markets Global   GlobeNewswire Inc
May 6, 2021
04:55PM EDT  IGM Biosciences Q1 EPS $(0.95) Down From $(0.58) YoY   Benzinga
May 3, 2021
08:03AM EDT  Urges Shareholders to Vote the WHITE Proxy Card FOR ALL Four of MIMEDXs Director Nominees Dr. Kathleen Behrens, Mr. Todd Newton, Mr. Timothy Wright, and Dr. Phyllis Gardner   GlobeNewswire Inc
Apr 27, 2021
07:00AM EDT  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Truist Securities Life Sciences Summit on May 4, 2021 at 4:20 p.m. EDT. The conference will be held in a virtual meeting format.   GlobeNewswire Inc
Apr 12, 2021
07:23AM EDT  IGM Biosciences Appoints George Gauthier As Chief Commercial Officer   RTTNews
Mar 30, 2021
04:18PM EDT  IGM Sees FY21 GAAP Opex $175M-$185M   Benzinga
04:18PM EDT  IGM Biosciences Q4 EPS $(0.79) Beats $(0.87) Estimate   Benzinga
04:17PM EDT  IGM Biosciences Announces Fourth Quarter and Full Year 2020   GlobeNewswire Inc
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
04:04AM EDT  Earnings Scheduled For March 30, 2021   Benzinga
Mar 27, 2021
01:01PM EDT  The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week   Benzinga
Mar 24, 2021
07:00AM EDT  IGM Biosciences, Inc.(Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and year-end 2020 financial results on Tuesday, March 30, 2021.   GlobeNewswire Inc
Mar 15, 2021
07:00AM EDT  IGM Biosciences Appoints Lisa Decker, Ph.D., as Chief Business Officer   GlobeNewswire Inc
Mar 8, 2021
09:51AM EST  5 Value Stocks In The Healthcare Sector   Benzinga
Feb 5, 2021
07:00AM EST  IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021   GlobeNewswire Inc
Jan 29, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 29, 2021   Benzinga
07:40AM EST  RBC Capital Initiates Coverage On IGM Biosciences with Outperform Rating, Announces Price Target of $121   Benzinga
Jan 19, 2021
06:28AM EST  HC Wainwright & Co. Maintains Buy on IGM Biosciences, Raises Price Target to $114   Benzinga
Jan 12, 2021
08:16AM EST  The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue   Benzinga
07:13AM EST  A Peek Into The Markets: US Stock Futures Up Ahead Of Fed Speakers; Crude Oil Rises   Benzinga
Jan 11, 2021
07:58PM EST  IGM Biosciences Enters Into Licensing Agreement With Medivir For Birinapant   RTTNews
06:03PM EST  IGM Biosciences Enters Into Exclusive Licensing Agreement With Medivir For Birinapant   Benzinga
06:00PM EST  IGM Biosciences Enters into Exclusive Licensing Agreement with   GlobeNewswire Inc
Jan 7, 2021
07:00AM EST  IGM Biosciences, Inc.(Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET.   GlobeNewswire Inc
Dec 22, 2020
11:54AM EST  IGM Biosciences shares were trading lower after Wedbush downgraded the stock from Outperform to Neutral.   Benzinga
10:02AM EST  Benzinga's Top Upgrades, Downgrades For December 22, 2020   Benzinga
08:45AM EST  Wedbush Downgrades IGM Biosciences to Neutral, Raises Price Target to $77   Benzinga
Dec 11, 2020
04:05PM EST  IGM Announces Closing of $230 Million Public Offering and Full   GlobeNewswire Inc
Dec 10, 2020
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
Dec 8, 2020
10:30PM EST  IGM Announces Pricing of Upsized $200 million Public Offering   GlobeNewswire Inc
Dec 7, 2020
05:08PM EST  IGM Biosciences Reports $150M Common Stock Offering   Benzinga
05:07PM EST  IGM Announces Proposed Public Offering   GlobeNewswire Inc
Dec 5, 2020
01:30PM EST  - 9 of 14 Patients Showed Reduction in Tumor Size, Including Two Recently Reported Complete Responses -   GlobeNewswire Inc
Nov 30, 2020
07:00AM EST  IGM Biosciences to Host Conference Call and Webcast to Review   GlobeNewswire Inc
Nov 29, 2020
08:59AM EST  The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions   Benzinga
Nov 23, 2020
07:00AM EST  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, has participated in a fireside chat in advance of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.   GlobeNewswire Inc
Nov 16, 2020
09:48AM EST  A Look Into Healthcare Sector Value Stocks   Benzinga
Nov 9, 2020
07:00AM EST  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at three upcoming investor conferences:   GlobeNewswire Inc
Nov 5, 2020
07:12AM EST  IGM Biosciences Q3 EPS $(0.66) Up From $(2.41) YoY   Benzinga
07:02AM EST  - Initial Data from Phase 1 Trial of IGM-2323 in Relapsed/refractory Non-Hodgkins Lymphomato be Presented at the 62nd American Society of Hematology Annual Meeting and Exposition in December -   GlobeNewswire Inc
Nov 4, 2020
09:21AM EST  IGM Biosciences Expects Tp Present First Clinical Data From Phase 1 Trial On IGM-2323 At 2020 ASH   RTTNews
09:21AM EST  IGM Biosciences Will Present Clinical Data From IGM-2323 In Non-Hodgkin's Lymphoma At American Society Of Hematology Dec. 5; 'Abstract Shows Encouraging Safety and Cytokine Release Data, Preservation of T cell Function and Repeatable T cell Activation'   Benzinga
09:20AM EST  IGM Biosciences to Present First Clinical Data from IGM-2323 in   GlobeNewswire Inc
Oct 21, 2020
10:13AM EDT  IGM Biosciences Shares Down 4.5% As Traders Circulate Short Report From Unknown/Unnamed Firm 'IGMS - The Next Big Biotech Collapse'   Benzinga
Sep 30, 2020
07:13AM EDT  IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-8444 for the Treatment of Solid Cancers and Non-Hodgkin's Lymphoma   Benzinga
07:10AM EDT  IGM Biosciences Initiates First-in-Human Clinical Trial Of IGM-8444 For Solid Cancers And Non-Hodgkin's Lymphoma   RTTNews
07:00AM EDT  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating IGM-8444, an IgM antibody targeting the Death Receptor 5 (DR5) protein, in patients with solid cancers and non-Hodgkins lymphoma.   GlobeNewswire Inc
Sep 24, 2020
04:03PM EDT  AbCellera, IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration; Terms Not Disclosed   Benzinga
04:02PM EDT  AbCellera, IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration   Benzinga
04:01PM EDT  AbCellera and IGM Biosciences Announce Multi-Year Antibody   GlobeNewswire Inc
Sep 13, 2020
11:06AM EDT  Notable Insider Buys Last Week: Keurig Dr Pepper, Xerox And More   Benzinga
Sep 2, 2020
07:00AM EDT  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at four upcoming investor conferences:   GlobeNewswire Inc
Aug 6, 2020
04:48PM EDT  IGM Biosciences Q2 EPS $(0.62)   Benzinga
Aug 4, 2020
07:00AM EDT  IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced thatFred Schwarzer, Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11 at 1:45 p.m. ET.   GlobeNewswire Inc
Jul 17, 2020
05:49AM EDT  Baird Initiates Coverage On IGM Biosciences with Outperform Rating, Announces Price Target of $90   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC